對付可怕的GT1b型丙肝，這個新藥厲害了！
來源丨醫學界消化肝病頻道
圖1：HCV基因1型是HCC發生的獨立預測因子 [10]
Zepatier自問世以來，歷經臨床試驗與實踐的雙重考驗，積累了大量的有效證據。在今年4月召開的歐洲肝臟研究學會年會上，來自美國的Puenpatom教授團隊報道的相關研究 [1]，納入了4755例HCV感染的退伍軍人，他們的生活方式具有酗酒、吸毒等特點，而且合併肝硬化、慢性腎病、糖尿病等疾病的比例也遠遠高於普通人群（圖2）。
圖:2：合併其他情況的患者比例
圖3：不同丙肝類型的SVR
總結：
參考文獻：
1.Abstractsof The International Liver Congress™ 2018 – 53rd annual meeting of the EuropeanAssociation for the Study of the Liver April 11–15,2018, Paris, France，JOURNAL OF HEPATOLOGY，VOLUME 68, SUPPLEMENT 1, PAGES S270.
2.Zeuzem S, Ghalib R, Reddy KR, et al.Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic andnoncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6Infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.
3.George J, Burnevich E, Sheen I, et al.Efficacy and safety of elbasvir/grazoprevir in treatment-naive subjects withchronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomizedmultinational clinical trial [abstract no. 76 plus conference report].Hepatology. 2016;64(Suppl 1):41A.
4.Kwo PY, Gane E, Peng C-Y, et al.Effectiveness of elbasvir and grazoprevir combination, with or withoutribavirin, for treatment experienced patients with chronic hepatitis Cinfection. Gastroenterology.2017;152(1):164–75.
5.Rockstroh JK, Nelson M, Katlama C, etal. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) inpatients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): anon-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27.
6.Hezode C, Colombo M, Bourliere M, etal. Elbasvir/grazoprevir for patients with hepatitis C virus infection andinherited blood disorders: a phase III study. Hepatology. 2017;66(3):736-745.
7.Kumada H, Suzuki F, Karino Y, et al.The combination of elbasvir and grazoprevir for the treatment of chronic HCVinfection in Japanese patients: a randomized phase II/III study. JGastroenterol. 2017;52(4):520–33.
8.Sperl J, Horvath G, Halota W, et al.Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylatedinterferon/ribavirin; a phase III randomized controlled trial. JHepatol.2016;65(6):1112–9.
9.Dore GJ, Altice F, Litwin AH, et al. Elbasvir–grazoprevir to treathepatitis C virus infection in persons receiving opioid agonist therapy: arandomized trial. Ann Intern Med. 2016;165(9):625–34.
10.Lee M-H et al. J Clin Oncol 2010;28:4587–4593.
閱讀更多 醫學界消化頻道 的文章
